Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

This study is testing a combination of two drugs — SHR-1210 (an immunotherapy drug that activates the immune system) and apatinib (a drug that blocks blood vessel growth in tumors) — given before surgery in people with a specific type of skin cancer called acral melanoma (occurring on the palms, soles, or under the nails) at an advanced but still potentially operable stage. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with acral melanoma at stage III or IV that can potentially be removed by surgery - You have at least one tumor that can be measured on a scan - You have not received any prior anti-cancer treatment for this condition - You are in good physical condition (ECOG 0–1) - Your blood counts and organ function meet minimum requirements **You may NOT be eligible if...** - You have already received any anti-tumor treatment - Your tumor cannot be measured or is not resectable - Your heart, liver, or kidney function does not meet study requirements - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.